In this individual ocrelizumab was used for 2 years. The person was vaccinated about two weeks after last infusion and the second Pfizer dose 3 weeks later. Nearly 3 weeks later they tested positive for COVID-19, so had been infected. A few days later there showed an IgM response but no IgG response. But we are no wiser…were they going to seroconvert to make an IgG response? No time to find out they were given anti-COVID antbody. So not that informative.
COVID–19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.Chilimuri S et al. Vaccines. 2021;9:219. The abstract proclaims “We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients”.
Sad to say they are wrong on both counts…
They submitted on 17 February 2021 – Accepted: 2 March 2021 -Published: 4 March 2021. But they suggest the solution is wait until the end of the cycle …however sorry to burst their bubble and the other first, first case report says that may not work either. I would ban the use of “this is the first”.. in any paper it is tyically rubbish as invarianbly it is not true..
Khayat-Khoei et al. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab, J Neurol. 2021 Feb 27 : 1–3.doi: 10.1007/s00415-021-10463-3. They submitted on Feb 5 2021 (2 weeks before the first), -Accepted 10 2021 (one week before the otehr was submitted) and published on 27 Feb (one week before the so called first paper)………however in the latter case here they waited to vaccinate just before the next infusion and that didn’t work either.
So I will save these up for MDs Saturday COVID lunch until we get the first paper to say that someone on ocrelizumab seroconverts and the paper with more than one or two people.